In this update, Ashley Yocum, PhD, executive research strategy lead of the Beat AML Master Trial at the Leukemia & Lymphoma Society, provides insights into the Beat AML…
In this expert interview, Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses donor selection for allogeneic stem cell transplantation in secondary acute myeloid leukemia (AML) patients…
In this presentation, Anand A. Patel, MD, reviewed the contemporary standard-of-care treatment roadmap for AML in 2025, covering key phases like induction chemotherapy (eg, the “7+3” regimen), consolidation…
Alice S. Mims, MD, of The Ohio State University’s James Comprehensive Cancer Center, provided an overview of current AML treatment options, such as FLT3 and IDH inhibitors, while…
In a presentation at the 2024 International Pathology Day virtual conference, Dr Justin Loke, CRUK/AACR Transatlantic Fellow, University of Birmingham, UK and Dana-Farber Cancer Institute, USA, explains how…
In an interview conducted at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy, Gail J. Roboz, MD, professor of medicine and director of the…
Patrick Connor Johnson, MD, Massachusetts General Hospital, Boston, Massachusetts, discusses real-world outcomes following treatment with lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Dr Johnson notes the…
Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
Manali Kamdar, MD, clinical director of lymphoma services, University of Colorado Cancer Center, Denver, Colorado, discusses the use of circulating tumor DNA as an early predictor of outcomes…
Michael Wang, MD, professor, Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, discusses results from the TRANSCEND-NHL-001 study, which was designed to investigate…
Rahul Banerjee, MD, assistant professor, Clinical Research Division, University of Washington Fred Hutchinson Cancer Center, Seattle, Washington, addresses the question of whether CAR T-cell therapy is a cure…
